What makes cancer stem cell markers different?

Por Karsten, Uwe, Goletz, Steffen
Publicado em 2013

Preliminary Safety Evaluation of a New Bacteroides xylanisolvens Isolate

Por Ulsemer, Philippe, Toutounian, Kawe, Schmidt, Jens, Karsten, Uwe, Goletz, Steffen
Publicado em 2012

A glyco-engineered anti-HER2 monoclonal antibody (TrasGEX) induces a long-lasting remission in a patient with HER2 overexpressing metastatic colorectal cancer after failure of all...

Por Eisner, Florian, Pichler, Martin, Goletz, Steffen, Stoeger, Herbert, Samonigg, Hellmut
Publicado no J Clin Pathol (2015)

Expression of CD176 (Thomsen-Friedenreich antigen) on lung, breast and liver cancer-initiating cells

Por Lin, Wei-Ming, Karsten, Uwe, Goletz, Steffen, Cheng, Ruo-Chuan, Cao, Yi
Publicado em 2011

Immunoreactivity of the fully humanized therapeutic antibody PankoMab-GEX™ is an independent prognostic marker for breast cancer patients

Por Heublein, Sabine, Mayr, Doris, Egger, Markus, Karsten, Uwe, Goletz, Steffen, Angele, Martin, Gallwas, Julia, Jeschke, Udo, Ditsch, Nina
Publicado no J Exp Clin Cancer Res (2015)

Proteomic and Postproteomic Characterization of Keratan Sulfate-Glycanated Isoforms of Thyroglobulin and Transferrin Uniquely Elaborated by Papillary Thyroid Carcinomas

Por Magro, Gaetano, Perissinotto, Daniela, Schiappacassi, Monica, Goletz, Steffen, Otto, Albrecht, Müller, Eva-Christina, Bisceglia, Michele, Brown, Gavin, Ellis, Timothy, Grasso, Sebastiano, Colombatti, Alfonso, Perris, Roberto
Publicado em 2003